Senolytic drugs relieve pain by reducing peripheral nociceptive signaling without modifying joint tissue damage in spontaneous osteoarthritis

• Published in: Aging (Albany, NY.) Vol. 14; no. 15; pp. 6006 - 6027
• Main Authors: Gil, Tae-Hwan, Zheng, Haiyan, Lee, Hyo Gyeong, Shin, Ji-Won, Hwang, Sun Wook, Jang, Ki-Mo, Jeon, Ok Hee
• Format: Journal Article
• Language: English
• Published: United States Impact Journals 10-08-2022
• Subjects: Animals; Humans; Mice; Nerve Growth Factor; Nociception; Osteoarthritis - metabolism; Pain; Pharmaceutical Preparations; Research Paper; Senotherapeutics; senescence; senolytics; pain; nociceptive pathways; spontaneous osteoarthritis
• ISSN: 1945-4589; 1945-4589
• DOI: 10.18632/aging.204204

Aging is a risk factor for the development of osteoarthritis (OA), a progressive joint disease leading to cartilage damage, pain, and loss of function. In a mouse model of OA, senolytic drugs to selectively clear senescent cells (SnCs) that accumulate with injury or aging yielded a chondroprotective effect; however, this therapeutic benefit was limited in aged mice. Due to inconsistency between cartilage destruction and pain-associated symptoms, we studied the therapeutic effect of senolytics on joint pain in spontaneous OA. We orally treated 21- and 22-month old mice with an ABT263 and Dasatinib and Quercetin (D+Q) drug combination. Selective elimination of the SnCs that accumulated in the articular cartilage and synovium by these two drugs did not alter cartilage degeneration and abnormal bone changes during spontaneous OA progression. Treatment reduced thermal and mechanical hyperalgesia associated with OA and peripheral sensitization through decreased expression of axon guidance proteins (nerve growth factor NGF/TrkA) and nociceptive neuron (calcitonin gene-related peptide, CGRP) projection to the synovium, subchondral bone marrow, and dorsal root ganglion, and knee joint angiogenesis. Selective removal of the SnCs from
cultures of synovial cells from human OA patients also decreased expression of senescent markers, axonal growth-promoting factors, such as NGF, and angiogenesis markers. We suggest that systemic administration of ABT263 and D+Q is an exciting therapeutic approach to age-related OA pain.